A simple, accurate, precise and highly selective reverse phase high performance liquid chromatographic (RP-HPLC) method was developed and validated for Pregabalin and Celecoxib.Chromatographic separation was achieved isocratically by using waters allaiance 2695 separation module, Hypersil BDS(150 mm x 4.6 mm, 5) at temperature 30 o c. Flow rate selected was 1ml/min. Both changes were identified with 238 nm. Mobile phase employed was potassium di hydrogen orthophosphate buffer of pH 6.5 and acetonitrile in the ratio of (70:30) which resulted best resolution and sensitivity. Developed method was validated in terms of linearity, range(37.5 µg/ml-281.25 µg/ml, for Pregabalin, 100 µg/ml -750 µg/ml Celecoxib), precession (correlation coefficient is less than 0.999), robustness, accuracy (recovery of Pregabalin and Celecoxib were 100.3% and 100.13% respectively). The validation of proposed method was verified by recovery studies and can be applicable in routine pharmaceutical analysis.KEYWORDS: RP-HPLC, Pregabalin, Celecoxib and potassium di hydrogen orthophosphate buffer.
The present work deals with development of two rapid , precise and accurate spectrophotometric methods for the estimation of Imatinib Mesylate in bulk and solid dosage form . Method A is area under the curve in which wavelength range 237-277nm was selected for estimation of Imatinib Mesylate . Method B is area under the curve in which wavelength range 400-800nm was selected for estimation of Imatinib Mesylate . Linearity was observed in the concentration range 2-10µg/ml for both the methods (r2=0.9992 for method A and method B). The results of analysis have been validated statistically, which confirm the accuracy and reproducibility of the methods. All the methods were found to be simple , precise and accurate and can be employed for routine quality control analysis of ImatinibMesylate in bulk as well as in its solid dosage form.
The current study mainly focused on treating cardiovascular diseases such as angina pectoris and chronic hypertension by modifying the existing commercial tablet available for Nifedipine. The limitation of Nifedipine is poor solubility, which comes under BCS class II drug category, which needs improvement in formulation to achieve better bioavailability. The objective of this research work is to enhance the oral bioavailability (first-pass metabolism in the liver (42–56%)) of Nifedipine by improving dissolution property. Sublingual fast dissolving tablets of Nifedipine formulated by sublimation method, designed to increase its disintegration time in the presence of saliva. This formulation is helpful for paediatric and geriatric patients who are unable to swallow the conventional tablet. Sublimation of camphor makes the tablet more porous and improve disintegration time as well. The direct compression method is used with different ratio of Croscarmellose Sodium (CS) and Sodium Starch Glycolate (SSG) as super disintegrants to formulate Nifedipine loaded Sublingual tablets. All formulations contain various ratio between super disintegrants and camphor, followed by the sublimation method. FTIR and DSC studies were conducted to investigate compatibility between drugs and disintegrants. Formulated tablets were subjected for precompression parameters, e.g., bulk density, tapped density, Carr’s index, Hausner’s ratio, angle of repose and for post-compression parameters, e.g. weight variation, thickness, hardness, friability, drug content, wetting time, disintegration time followed by dissolution study and found satisfactory as per IP.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.